Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin
徐建芳,周彩存
DOI: https://doi.org/10.3969/j.issn.1007-4406.2001.01.002
2001-01-01
Abstract:AIM: To evaluate the efficacy and toxicity of the chemotherapycombining gemcitabine (Gem) and cisplatin (Cis) in advanced non-small cell lung cancer (NSCLC). METHODS: Two treatment cycles with 21 d for each cycle were needed. Gem-Cis combination study (A group): the dosage was 1 000 mg/m2, iv gtt, qd, at d 1, 8, 15 for Gem and 80 mg/m2, iv gtt, qd, at d 1, 2, 3 for Cis respectively. Mitomycin (Mit), vindesine (Vin) plus Cis combination study (B group): the dosage was 8 mg/m2, iv gtt, at d 1 for Mit, 3 mg/m2, iv gtt, qd, at d 1, 8, 15 for Vin and 80 mg/m2 iv gtt, qd, at, d 1, 2, 3 for Cis respectively. RESULTS: A group of total 13 cases, 7 got partial remission, 5 no change, 1 progression of diease, and the efficiency rate was 53.8% in A group. B group: the total 24 cases, 10 got partial remission, 10 no change, 4 progression of disease, and the efficiency rate was 41.7%. For comparison, significant difference was observed in efficacy between combination chemotherapy of Gem plus Cis and Mit, Vin plus Cis (P＜0.05), and the bone marrow suppression and gastrointestinal tract adverse drug reactions for combination with Gem plus Cis were relatively weak (P＜0.05). CONCLUSION: The combined chemotherapy of Gem and Cis, with its low toxicity and high tolerance, is an ideal regimen for advanced NSCLC.